Compassionate Use of Remdesivir for Patients with Severe Covid-19

Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2.

53 patients hospitalized for severe Covid-19 were treated with compassionate-use remdesivir. Clinical improvement was observed in 36 of 53 patients (68%). A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation.

https://www.nejm.org/doi/full/10.1056/NEJMoa2007016